147819-32-7
Chemical Structure
JB-1
- CAS. Nr.: 147819-32-7
- Formula:C55H88N14O15S2
- Molecular Weight:1249.50
IUPAC Name: (6S,9S,12S,15R,20R,23S,26S,29S,31aS,37S,40S,42aS)-15-amino-26,37-bis(4-aminobutyl)-12-(4-hydroxybenzyl)-23-(hydroxymethyl)-40-isobutyl-6,9,29-trimethyl-5,8,11,14,22,25,28,31,36,39,42-undecaoxooctatriacontahydro-1H,19H-dipyrrolo[2,1-p:2',1'-y][1,2]dithia[5,8,11,14,17,20,23,26,29,32,35]undecaazacyclooctatriacontine-20-carboxylic acid
InChIKey: MPUVBZQBFGGAAS-XHGDPFBQSA-N
SMILES: O=C1N2[C@@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N3[C@](CCC3)([H])C(N[C@H](C(N[C@H]1CCCCN)=O)CC(C)C)=O)=O)C)=O)C)=O)CC4=CC=C(C=C4)O)=O)N)C(O)=O)=O)CO)=O)CCCCN)=O)C)=O)([H])CCC2
Biological Activity: JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy[1].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JB-1 | 99.63% | JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
